Incannex Healthcare Share Price and Company Fundamentals
Last traded: Yesterday at 6:10 AM
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated 2001 and is based in Sydney, Australia.
|Industry / Sector||Drug Manufacturers—Specialty & Generic / Healthcare|
|Full time employees||3|
|Mailing address||207/11 Solent Circuit Norwest Sydney NSW 2153 Australia|
|Phone / Fax||/|
|Share registry||AUTOMIC REGISTRY SERVICES|
Incannex Healthcare does not pay dividends.
As of Sep 2021, following are the company executives and directors listed on Incannex Healthcare.
|Mr. Joel Bradley Latham||MD, CEO & Exec. Director||31||418.36k|
|Dr. Sudhanshu Agarwal B.Sc.||Chairman of Medical Advisory Board, Chief Medical Officer & Non-Exec. Director||45||142.56k|
|Mr. Madhukar Bhalla||CFO & Company Sec.||62|
|Dr. Mark Bleakley||CSO & Member of the Advisory Board|
|Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D.||Chief Exec. Officer of IncannexTM|
|Ms. Rosemarie Walsh||Clinical Research Mang. & Member of the Advisory Board|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Incannex Healthcare is 438.47M and its enterprise value is 395.14M. The enterprise value to revenue ratio of IHL is 208.23.
The IHL's stocks Beta value is 2.10 making it 110% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Incannex Healthcare (IHL)
Incannex Healthcare (ASX:IHL) Frequently Asked Questions
1. What is Incannex Healthcare's Stock Symbol?
Incannex Healthcare trades on ASX under the ticker symbol "IHL".
2. What is Incannex Healthcare's stock price today?
One share of IHL stock can currently be purchased for approximately $0.375.
3. How can I contact Incannex Healthcare?
Incannex Healthcare's mailing address is 207/11 Solent Circuit Norwest Sydney NSW 2153 Australia. The company can be reached via phone at .
4. What is Incannex Healthcare's official website?
The official website of Incannex Healthcare is http://www.incannex.com.au.
5. Which share registry manages Incannex Healthcare's stock?
Incannex Healthcare's stock is managed by AUTOMIC REGISTRY SERVICES.